Cost-effectiveness of live oral attenuated human rotavirus vaccine in Tanzania

Cost-effectiveness of live oral attenuated human rotavirus vaccine in Tanzania

BACKGROUND Globally, diarrhoea is the second leading cause of morbidity and mortality, responsible for the annual loss of about 10% of the total global childhood disease burden. In Tanzania, Rotavirus infection is the major cause of severe diarrhoea and diarrhoeal mortality in children under five years. Immunisation can reduce the burden, and Tanzania added rotavirus vaccine to its national imm...

RIX4414 (Rotarix): a live attenuated human rotavirus vaccine.

report. New York: Oxford University; 2005. 4. Fortes Filho JB, Barros CK, daCostaMC, ProcianoyRS. Results of a program for the prevention of blindness caused by retinopathy of prematurity in southern Brazil. J Pediatr (Rio J). 2007;83:209-16. 5. Gilbert C, Fielder F, Gordillo L, Quinn G, Semiglia R, Visintin P, et al. Characteristics of infants with severe retinopathy of prematurity in countrie...

RotaTeq, INN-Rotavirus vaccine, live, oral

A review of prophylactic measure against brucellosis in human with a live attenuated vaccine

Development of a New Live Attenuated Mumps Virus Vaccine in Human Deploid Cells